Coronavirus (COVID-19) updates, visitor restrictions and resources →
Now offering telemedicine through our Virtual Visit online program for primary care and specialty care visits → Virtual Visit appointments are available for new and existing UF Health patients. Check the FAQ section and Request an Appointment section below for more information.

Call (904) 383-1052 to make an appointment or call your physician’s office if you have questions specific to your health needs.

Clinical Trial Details

A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis
Study Description

This is a clinical research study. This trial is sponsored by the pharmaceutical company named Novartis. If you agree to join in this study, you may get either BAF312 or placebo. An unequal randomization ratio (random selection) of 2:1 in favor of BAF312 was chosen to gain more experience on the treatment in the SPMS population with BAF312 and to increase the clinical data on the safety aspect.

You will be asked to take one tablet a day throughout your participation in the study. The duration of treatment in the study will vary from approximately 23 months (if you are entered later in the study) to 42 months (if you are entered earlier in the study). The duration of treatment will not exceed 60 months for any patient. It is currently estimated that you will be treated in the study between 23 months (15 scheduled visits) and 42 months (22 scheduled visits) depending on when you joined the study.

Open Enrollment
Contact Name: Yasmeen Shabbir
Contact Phone: (904) 244-9814
Contact Email:

Principal Investigator
Scott L. Silliman, M.D.